Adam Brufsky

机构：University of Pittsburgh, UPMC Health System, Magee-Womens Hospital, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center · ORCID：0000-0001-8080-7960

发表论文 1046 篇 · 总被引 38122 次 · h-index 95

代表论文

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial (2026 · The Lancet Oncology · 被引 7)
Multi-modal AI for comprehensive breast cancer prognostication (2026 · Nature Communications · 被引 6)
Abstract RF7-03: Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (2026 · Clinical Cancer Research · 被引 6)
Abstract RF5-03: OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer (2026 · Clinical Cancer Research · 被引 6)
Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-03 study of participants (pts) with previously untreated metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) vs chemotherapy (chemo). (2026 · Journal of Clinical Oncology · 被引 3)
Efficacy and Genomic Analysis of HER2 -Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial (2026 · Clinical Cancer Research · 被引 3)